Abstract: Lung cancer is the most common malignant disease with the highest mortality， among which non-small cell lung cancer（NSCLC） accounts for nearly 85% of all cases. The first-line treatment for NSCLC is surgery， followed by chemotherapy in order to improve overall survival. However， only 4% - 15% patients demonstrate improved treatment benefit， while chemotherapy-related side effects greatly worsen the quality of life and increase non-tumor-related mortality. EGFR-TKIs are important treatment options for late stage NSCLC with EGFR mutations. Whether or not EGFR-TKIs can be used in intermediate stage NSCLC needs further validation. In this article， we review and discuss the topics on EGFR-TKIs as adjuvant therapy in post-surgery of NSCLC.